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ABSTRACT
Background Clinicians are faced with unprecedented
opportunities to identify the genetic aetiologies of
hitherto molecularly uncharacterised conditions via the
use of high-throughput sequencing. Access to genomic
technology and resultant data is no longer limited to
clinicians, geneticists and bioinformaticians, however;
ongoing commercialisation gives patients themselves ever
greater access to sequencing services. We report an
increasingly common medical scenario by describing two
neuromuscular patients—a mother and adult son—
whose consumer access to whole-genome sequencing
affected their diagnostic journey.
Results Whole-genome sequencing initiated by the
patients—to predict their risk of common diseases—
revealed that they share several variants potentially
relevant to neuromuscular diseases, which initially
sidetracked diagnostic efforts. Since eventual clinical
reassessment, including muscle imaging, pointed
towards Bethlem myopathy, a collagen VI-related
myopathy, we pursued Sanger sequencing of COL6A1,
COL6A2 and COL6A3. This targeted approach revealed a
heterozygous causative variant in COL6A3 (c.6365G>T
(p.Gly2122Val)), shared by both individuals, that was
not flagged by the interpretation of the whole-genome
sequencing data.
Conclusions This report highlights the essential
interplay of clinical and genomic expertise in realising
the potential of high-throughput sequencing. In an era
when patients themselves may bring their own data to
the table, definitively identifying clinically significant
genomic variants will require close collaboration among
clinicians, geneticists and bioinformaticians.
INTRODUCTION
‘We had everything before us, we had nothing
before us’
Charles Dickens, A Tale of Two Cities
The advent of high-throughput sequencing has
ushered in an era of tremendous potential for iden-
tifying the molecular causation of simple and
complex disorders, rare and common. Advantages
of whole-genome sequencing over targeted, exon
capture approaches in genetically heterogeneous
Mendelian disorders were reported by Lupski et al
in 2010.1 Since then, the identification of new
disease genes, as well as causative variants in
known genes, has proceeded at a remarkable pace.
The successes of whole-genome sequencing
reflect the combined interpretive skills of
geneticists, bioinformaticians and clinicians
working in close collaboration. Indeed, this essen-
tial interplay of complementary genomic and clin-
ical expertise is epitomised by the recent
identification of new genes in hitherto molecularly
uncharacterised conditions. Importantly, patients’
own independent access to genomic technology
may catalyse such interaction but may also steer the
diagnostic journey from its conventional path, with
varied results. The following case highlights this
contemporary medical scenario and serves as an
instructive tale.
Case reports
The proband, a 33-year-old male, presented to our
(RDSP and MGH) neuromuscular centre in
London in 2004. He was never able to run, and he
had developed slowly progressive proximal weak-
ness beginning in his teenage years. Examination
revealed bilateral elbow contractures, Achilles
tendon tightness and proximal muscle weakness
(Medical Research Council (MRC)-grade 4/5).
Deep tendon reflexes were present. Creatine kinase
was 354 IU (reference range: <150 IU). Muscle
biopsy revealed evidence of muscle fibre necrosis
and regeneration, consistent with an underlying
dystrophy (figure 1A–D).2
The patient’s mother reported a similar history,
albeit with a later onset, with proximal muscle
weakness noted around age 30 years and progres-
sing to dependence on a cane for walking by age
60 years. Muscle biopsy was reported as
dystrophic-appearing but was not available for
review.
No other family members were noted to have
similar features. The family was counselled that
their condition was likely a form of autosomal
dominant muscular dystrophy, with Bethlem myop-
athy and Emery-Dreifuss muscular dystrophy
included in the differential diagnosis. Further inves-
tigations were recommended; however, the family
did not return to our clinic for the ensuing 5 years.
When the family returned in 2010, they brought
an electronic data storage device with their anno-
tated whole-genome sequence data, obtained—in
order to predict their risk of common diseases—
through sequencing contracted through our ( JH,
NMP) genome interpretation company in Boston.
Analysis of the kindred genome data flagged
protein-altering non-reference variants in 22 neuro-
muscular disease-implicated genes that were called
in the proband and his mother but not the pro-
band’s unaffected father or wife (unrelated), who
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also underwent whole-genome sequencing. The strongest such
candidate, however, was a heterozygous missense variant in
COL6A1 that is modestly common (∼8% allele frequency) in
the general population and could not alone plausibly underlie
the phenotype.
Two other neuromuscular disease-implicated genes (SGCA
and SGCG) were each called with a heterozygous
protein-altering variant shared by the proband and his mother.
Variants in these genes have been recessively (or within one
gene compound heterozygously) implicated in sarcoglycanopa-
thies, but we knew of no report tracing disease to interaction
between heterozygous variants in distinct sarcoglycan genes.
Moreover, the clinical phenotype of the patients was not con-
sistent with phenotypes associated with sarcoglycanopathies. As
such, the clinical and genome interpretation teams began a close
dialogue, to best integrate the initially inconclusive genomic
findings with detailed clinical findings, for further diagnostic
insight.
In order to further elucidate the patients’ pattern of muscle
involvement and decipher the potential relevance of genetic var-
iants of unknown significance, we (ARF, RDSP, FM and MGH)
recommended lower extremity muscle MRI be performed, since
it can be instrumental in narrowing the differential diagnosis and
pointing towards particular genetic aetiologies.3 Notably, with
this recommendation the patients returned to the original diag-
nostic pathway. MRI in the proband and his mother revealed
abnormal signalling in the central region of the rectus femoris
muscle, consistent with a pattern termed ‘central shadow’ and
abnormal signalling along the periphery of the vastus lateralis
muscle, a pattern described as ‘outside-in’ (figure 1E,F). These
muscle MRI findings have been reported in patients with
Bethlem myopathy,4 5 resulting from pathogenic variants in any
of the 3 collagen 6 genes (COL6A1, COL6A2 and COL6A3).6–8
Given this muscle MRI pattern strongly evocative of Bethlem
myopathy and consistent with our clinical impression, and since
causative variant(s) in the collagen 6 genes were not flagged by
the interpretation of the whole genome sequencing data, we
pursued follow-up long-read (Sanger) sequencing of COL6A1,
COL6A2 and COL6A3 in a diagnostic laboratory in London.
Strikingly, the targeted sequencing and interpretation flagged a
heterozygous c.6365G>T (p.Gly2122Val) novel variant in exon
20 of COL6A3 in the proband and his mother. Such variants, in
the triple helical domain of the collagen VI protein, are known
to result in aberrant formation of the extracellular matrix
protein collagen VI, resulting in a spectrum of collagen
VI-related myopathies ranging from Bethlem myopathy to the
more severe and allelic condition Ullrich congenital muscular
dystrophy.9 While Bethlem myopathy typically follows auto-
somal dominant inheritance, rare autosomal recessive inherit-
ance has been described as well.10 11
Skin biopsies performed in the proband and his mother for
dermal fibroblast collagen VI immunocytochemistry and flow
cytometry studies (performed as described in Kim et al12)
revealed abnormal collagen VI expression (see online
supplementary figure S1A,B), thus providing further evidence of
collagen VI deficiency. Sequencing of complementary DNA,
Figure 1 Muscle biopsy performed in the proband reveals variation in fibre size on H&E stain (A) and evidence of necrotic fibres (inset, A).
Core-like areas are evident on nicotinamide adenine dinucleotide-tetrazolium reductase (NADH-TR) (B) and cytochrome oxidase (COX) (C) staining.
COX-negative fibres are also evident (C). Fibres positive for neonatal myosin likely indicate regenerating fibres (D). Bar in A represents 50 μm in A–C
and inset in A, and 100 μm in D. Muscle MRI with axial cuts through mid-thigh region of the proband (E) and his mother (F) reveals abnormal
signalling in the central region of the rectus femoris muscle (‘central shadow’ pattern) (arrowheads) and abnormal signalling along the periphery of
the vastus lateralis muscle (‘outside-in’ pattern) (arrows). (Signal artefact in left leg of proband’s mother (F) due to metallic implant.)
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extracted from skin fibroblasts, confirmed the presence of the
COL6A3 glycine-altering variant called in the proband and his
mother’s genomic DNA, which did not result in abnormal
splicing.
In arriving at a diagnosis of Bethlem myopathy, other clinic-
ally similar conditions such as Emery-Dreifuss muscular dys-
trophy (and its associated cardiac involvement) were excluded.
Counselling regarding the natural history of Bethlem myopathy,
its autosomal dominant inheritance pattern in this family and
the associated risk of recurrence were provided to the proband
and his mother in the setting of our (RDSP and MGH) neuro-
muscular centre. In contrast, when the family received the anno-
tated data of their independently contracted whole-genome
sequencing and interpretation, they did not have genetic
counselling.
Re-analysis of the whole-genome sequencing data confirmed
that the causative COL6A3 variant was detected, but not inter-
pretively flagged, due to the inadequacy of our ( JH, NMP)
pipeline (at the time) for predicting functional effects of variants
in whole-genome analysis. Specifically, our whole-genome ana-
lysis pipeline relied on data published in conjunction with the
SIFT (Sorting Intolerant From Tolerant) algorithm to identify,
and optionally functionally prioritise, missense variants. At the
time, SIFT annotated the COL6A3 transcript in question on the
wrong strand, and our pipeline did not yet correct, or flag, such
discrepancies. By contrast, the conventional pipeline used to
interpret targeted sequencing of collagen genes successfully
flagged the variant in question as functionally relevant/poten-
tially deleterious.
DISCUSSION
The diagnostic journey outlined here is provocative for several
reasons. First of all, whole-genome sequencing independently
pursued by our patients did not uncover the causative COL6A3
variant. Instead, this variant was identified by Sanger sequencing
of the collagen 6 genes, motivated by muscle MRI findings, per
the conventional diagnostic pathway. While whole-genome ref-
erence data have since improved to better flag potentially
harmful variants in COL6A3, whole-genome sequencing and
interpretation will likely remain ‘blind’ to some variants that tar-
geted methods identify more reliably. Such whole-genome short-
comings are inherent to methods of short-read sequencing
(patchiness of coverage; and inadequacy of alignment, variant-
calling and haplotyping methods) and interpretation (inaccuracy
of predictive algorithms; and patchiness of comparative data
from healthy controls). Conventional locus-specific databases,
such as those available through the Leiden Open Variation
Database (LOVD), may contain more reliable data on particular
genes than do sources casting a broader net on our genomes.
Such locus-specific databases cover only particular genes, and
use sundry formats that defy easy integration for whole-genome
interpretation, but they will likely remain a cornerstone of inter-
pretation in difficult cases.
Second, this case highlights muscle MRI as a valuable diag-
nostic tool for Bethlem myopathy, for which it reportedly
yielded 96% diagnostic specificity in a study of patients with
Bethlem myopathy and other muscular dystrophies presenting
with rigid spine.13
Third and most importantly, the diagnostic trajectory
described here highlights the indispensable role of clinical
expertise in the era of genomic medicine. Clinicians, geneticists
and bioinformaticians together face the challenge of wading
through an immense quantity of data from patient genomes—a
challenge compounded if any of them tries to navigate these
waters in isolation.
The commercialisation of high-throughput sequencing alters the
landscape of information available to patients, yielding vast data
but no easy means to definitively interpret it. Notably,
clinician-initiated high-throughput sequencing is now widely avail-
able, but always requires formal ethics oversight and, if for
research, express institutional approval. By comparison, restric-
tions on consumer-initiated sequencing vary more widely and in
some jurisdictions allow detailed genomic data to be directly avail-
able to patients and their relatives—data that will often then be
presented to a clinician for review, as in this case. Given the rapid
decline of the cost of whole-genome sequencing, many clinicians
may soon confront the scenario presented here. Indeed, cost is no
longer the limiting factor in whole-genome sequencing, which in
2001 cost ∼US$100 000 000 but in 2011 fell below US$10 000
(National Human Genome Research Institute).14 Rather, interpret-
ive expertise—genomic and clinical—is emerging as the limiting
factor, in temporal and cost terms.
The greatest hurdle to the use of high-throughput sequencing
in clinical practice may, in fact, be time. Genomicists, bioinfor-
maticians and clinicians worldwide must work together, care-
fully and patiently scrutinising immense quantities of genomic
data, on a joint quest to identify variants of clinical significance.
Without coordinated, dedicated efforts, the course of genomic
medicine risks Dickens’ admonition: ‘we had everything before
us, we had nothing before us.’15
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